Hexarelin vs GHRP-6
GHRP · GHRP
Here is how these two compounds compare, based on published research, not marketing claims.
Hexarelin
The most potent GH secretagogue by single-dose peak, with a unique cardioprotective mechanism through CD36 receptor binding.
GHRP-6
The first-generation GH secretagogue with the most pronounced appetite effect and the broadest published pharmacological characterization.
Hexarelin
311 studies
30 human trials
Not FDA-Approved
GHRP-6
778 studies
2 human trials
Not FDA-Approved
What it does
Hexarelin
Triggers the largest single-dose growth hormone pulse of any GH secretagogue documented. Also studied for cardioprotective effects through a separate receptor pathway (CD36) independent of GH release.
GHRP-6
Produces the strongest hunger response of any growth hormone secretagogue in published research. The original hexapeptide that demonstrated ghrelin-receptor activation in humans, with historical research applications where both growth hormone and appetite stimulation were the desired endpoints (cachexia, recovery from severe illness, age-related muscle loss). Cortisol and prolactin elevation in trial data is smaller than GHRP-2 but documented.
How it works
Hexarelin
Hexarelin is a synthetic hexapeptide that activates the ghrelin receptor (GHS-R1a) on pituitary somatotrophs, producing the largest acute GH release in the GHRP class. Like GHRP-2 and GHRP-6, hexarelin raises cortisol and prolactin alongside GH. Uniquely, hexarelin also binds the CD36 scavenger receptor on cardiac tissue, producing cardioprotective effects in animal models that appear independent of its GH-releasing activity. This dual mechanism (GH release plus cardiac protection) distinguishes hexarelin from other GH secretagogues.
GHRP-6
GHRP-6 is a synthetic hexapeptide that activates the ghrelin receptor (GHS-R1a) on the pituitary gland. The compound produces robust growth hormone release but with the broadest off-target profile in the GHRP class: cortisol elevation, prolactin elevation, and intense appetite stimulation through the same ghrelin signaling that drives hunger. The appetite effect is more pronounced than GHRP-2 and substantially more than ipamorelin.
How often
Hexarelin
In published human studies, hexarelin has been administered as subcutaneous or intravenous injection. No FDA-approved product exists. Research protocols vary. The compound shows tachyphylaxis (reduced response with repeated dosing) more rapidly than some other GH secretagogues.
GHRP-6
In published research, GHRP-6 has been administered as subcutaneous or intravenous injection in single-dose and repeated-dose study designs. No FDA-approved product exists. Research protocols vary.
How strong
Hexarelin
Strongest acute GH pulse in the class. The cardioprotective research through CD36 receptor binding is a unique mechanistic feature not shared by other GH secretagogues. Multiple human pharmacodynamic studies confirm the GH-release magnitude.
GHRP-6
Strong GH release with the most extensively characterized pharmacology of any GHRP. Published human studies span multiple decades. The appetite stimulation effect has itself been studied as a model for ghrelin-mediated hunger signaling research.
Main tradeoff
Hexarelin
Tachyphylaxis limits sustained use: the GH response diminishes with repeated dosing more rapidly than with ipamorelin or GHRP-2. Cortisol and prolactin elevation accompanies the GH release. Not FDA-approved. The cardioprotective mechanism is promising but remains primarily characterized in animal models.
GHRP-6
The broadest off-target hormonal profile in the GH secretagogue class. Cortisol, prolactin, and appetite effects are all more pronounced than GHRP-2 or ipamorelin. Most researchers and clinicians have moved to ipamorelin for GH research because it achieves GH release without these off-target effects. GHRP-6 retains relevance as a reference compound and for research specifically studying ghrelin-mediated appetite pathways.
Best for
Hexarelin
- Research on peak GH release magnitude and pituitary reserve testing
- Research on CD36-mediated cardioprotective pathways independent of GH
- Research comparing GH secretagogue potency versus selectivity trade-offs across the class
GHRP-6
- Research specifically studying ghrelin-mediated appetite signaling
- Historical reference compound for GH secretagogue class comparison
- Research contexts where the broadest pharmacological challenge test is needed
How to choose
A good fit for Hexarelin
- Research on peak GH release magnitude and pituitary reserve testing
- Research on CD36-mediated cardioprotective pathways independent of GH
- Research comparing GH secretagogue potency versus tachyphylaxis trade-offs
A good fit for GHRP-6
- Research specifically studying ghrelin-mediated appetite signaling
- Historical reference compound for GH secretagogue class pharmacology
- Research contexts where the broadest pharmacological challenge test is needed
Consider both across time
Hexarelin and GHRP-6 are both first-generation non-selective GH secretagogues that most researchers have moved past in favor of ipamorelin for clinical GH protocols. Their value is in specialized research: hexarelin for peak GH magnitude studies and CD36-mediated cardioprotection research; GHRP-6 for ghrelin-mediated appetite signaling and as the longest-studied reference compound in the class. Both raise cortisol and prolactin. Neither is used as a first-line GH secretagogue in current clinical practice.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- GHS-R1a Receptor
- CD36 Scavenger Receptor
- GHS-R1a Receptor activates Pituitary Somatotrophs
- Pituitary Somatotrophs stimulates Peak GH Release
- GHS-R1a Receptor elevates Cortisol Elevation
- GHS-R1a Receptor elevates Prolactin Elevation
- CD36 Scavenger Receptor mediates Cardioprotective Signaling
- Pituitary Somatotrophs stimulates Growth Hormone Release
- GHS-R1a Receptor triggers Ghrelin-Mediated Appetite
Hexarelin activates both the ghrelin receptor (GHS-R1a) for GH release and the CD36 scavenger receptor for cardioprotective signaling.
GHRP-6 activates the ghrelin receptor with the broadest off-target profile in the class, including the strongest ghrelin-mediated appetite stimulation.
Research Evidence
GHRP-6 has the more extensive published pharmacology: multi-decade research spanning GH-release kinetics, appetite signaling, and receptor characterization. Hexarelin has multiple human pharmacodynamic studies confirming peak GH release magnitude plus a separate body of animal research on CD36-mediated cardioprotection. The CD36 cardioprotective mechanism is hexarelin's distinguishing research contribution, and it appears independent of the GH-releasing pathway. Neither compound has completed Phase III trials.
- 1.
For GH stimulation with cardiac research interest, hexarelin has unique data.
- 2.
For appetite stimulation (e.g., underweight patients), GHRP-6 has the strongest orexigenic effect.
- 3.
For minimizing side effects, neither is ideal, consider ipamorelin instead.
- 4.
For research on GH release potency, both are established tools.
Key Limitations
- •No direct head-to-head clinical trial.
- •Both are non-selective with off-target hormone effects.
- •Hexarelin's cardiac benefits need larger confirmatory trials.
- •GHRP-6's appetite effect limits its use in obesity-related applications.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Hexarelin
"Hexarelin is the strongest GH releaser available"
Supported by evidence
"Hexarelin protects the heart directly"
Supported by evidence
GHRP-6
"GHRP-6 is the strongest appetite stimulant of all the GH peptides"
Supported by evidence
"GHRP-6 has anti-aging benefits beyond just GH"
Plausible but limited human data
Safety Comparison
Both compounds raise cortisol and prolactin alongside GH, a feature of their non-selective ghrelin receptor activation. Hexarelin shows more rapid tachyphylaxis (diminishing GH response with repeated dosing) than GHRP-6 or other GH secretagogues, which limits its utility for sustained protocols. GHRP-6's appetite stimulation is more intense than any other compound in the class and may be a concern or a feature depending on the research context. Neither has long-term human safety data. Both have been substantially displaced by ipamorelin's cleaner selectivity profile.
Hexarelin
Raises cortisol and prolactin. Potential cardiac benefits are under investigation. Not FDA-approved.
GHRP-6
Significant appetite increase. Raises cortisol and prolactin. Used clinically in research settings.
What the Research Suggests
Hexarelin has the more interesting research profile due to its cardiac data. GHRP-6 has more total publications but a worse side effect profile. For pure GH stimulation, both work. For a secondary benefit, hexarelin's cardiac angle is unique.